Announcement from Wecome Pharmaceutical (300878.SZ): The company plans to transfer 100% equity of its wholly-owned subsidiary Wecome Retail to Fujian Rongchuang No.2 Investment Co., Ltd., and transfer 100% equity of its wholly-owned subsidiary Wecome Pharmacy to Fujian Rongchuang No.3 Investment Co., Ltd. On May 27, 2024, an announcement was made regarding the planned sale of subsidiary equity and the signing of a letter of intent. Fujian Rongchuang No.2 Investment Co., Ltd. and Fujian Rongchuang No.3 Investment Co., Ltd. plan to purchase the target assets by paying cash. The transfer price for 100% equity of Wecome Retail is 95 million yuan, and the transfer price for 100% equity of Wecome Pharmacy is 8 million yuan.
According to an announcement from Wecome Pharmaceutical (300878.SZ) on the Zhitong Finance App, the company plans to transfer 100% equity of its wholly-owned subsidiary Wecome Retail to Fujian Rongchuang No.2 Investment Co., Ltd., and transfer 100% equity of its wholly-owned subsidiary Wecome Pharmacy to Fujian Rongchuang No.3 Investment Co., Ltd. On May 27, 2024, an announcement was made regarding the planned sale of subsidiary equity and the signing of a letter of intent. Fujian Rongchuang No.2 Investment Co., Ltd. and Fujian Rongchuang No.3 Investment Co., Ltd. plan to purchase the target assets by paying cash. The transfer price for 100% equity of Wecome Retail is 95 million yuan, and the transfer price for 100% equity of Wecome Pharmacy is 8 million yuan.
The announcement stated that through this equity sale, it is beneficial for the company to concentrate its advantageous resources on the pharmaceutical manufacturing industry and continue to promote the coordinated development of modern traditional Chinese medicine and Western medicine.